Reduction of FXIII during myelosuppression in acute leukemia after chemotherapy and adverse relation with bleeding events.
10.3760/cma.j.issn.0253-2727.2020.01.011
- Author:
Yan Zhi WANG
1
;
Bang Yun TAN
2
;
Lin LI
2
;
Zi Jian LI
1
Author Information
1. Department of Hematology, First Hospital of Lanzhou University, Lanzhou 730000, China.
2. Department of Laboratory, First Hospital of Lanzhou University, Lanzhou 730000, China.
- Publication Type:Journal Article
- Keywords:
Acute leukemia;
Bleeding event;
Coagulation factor XIII;
Myelosuppression
- MeSH:
Acute Disease;
Blood Coagulation Tests;
Factor XIII;
Factor XIII Deficiency;
Hemorrhage;
Humans;
Leukemia
- From:
Chinese Journal of Hematology
2020;41(1):59-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the relationship between plasma coagulation factor XIII (FXIII) and bleeding events. Methods: A total of 55 cases of acute leukemia (AL) at the myelosuppression phase after chemotherapy hospitalized in our hospital from August 2017 to March 2018 were enrolled, with 35 normal controls. The concentration of plasma coagulation factor XIII (FXIII) was detected by ELISA to determine the relationship between the plasma FXIII levels in AL patients at the myelosuppression phase after chemotherapy with bleeding events. Results: The level of FXIII in AL patients at the myelosuppression phase after chemotherapy was significantly lower than that in controls (P<0.001) . The level of FXIII was inversely related with the bleeding severity (the Spearman correlation coefficient -0.761) . Given the diagnosis cut-off point of FXIII concentration as 103.9 μg/L, the sensitivity of diagnosing bleeding in AL patients at the myelosuppression phase after chemotherapy was 0.939, and the specificity 0.909. Conclusion: AL patients at the myelosuppression phase after chemotherapy had low level of plasma FXIII, and patients with lower plasma FXIII associated with higher incidence and severity of bleeding. FXIII level was an independent influencing factor of bleeding in AL patients at the myelosuppression phase after chemotherapy.
